AllianceBernstein’s Cymabay Therapeutics CBAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-349,739
Closed -$8.26M 3196
2023
Q4
$8.26M Buy
349,739
+248,739
+246% +$4.43M ﹤0.01% 1259
2023
Q3
$1.51M Hold
101,000
﹤0.01% 2031
2023
Q2
$1.11M Buy
+101,000
New +$940K ﹤0.01% 2228
2022
Q2
Sell
-106,600
Closed -$332K 3420
2022
Q1
$332K Buy
106,600
+400
+0.4% +$1.26K ﹤0.01% 2840
2021
Q4
$359K Hold
106,200
﹤0.01% 2885
2021
Q3
$388K Hold
106,200
﹤0.01% 2858
2021
Q2
$463K Buy
106,200
+8,600
+9% +$38.1K ﹤0.01% 2840
2021
Q1
$443K Hold
97,600
﹤0.01% 2712
2020
Q4
$560K Sell
97,600
-9,000
-8% -$68.1K ﹤0.01% 2544
2020
Q3
$772K Hold
106,600
﹤0.01% 2302
2020
Q2
$372K Sell
106,600
-30,800
-22% -$88.9K ﹤0.01% 2791
2020
Q1
$203K Buy
137,400
+20,600
+18% +$34.6K ﹤0.01% 2796
2019
Q4
$229K Hold
116,800
﹤0.01% 2879
2019
Q3
$598K Buy
116,800
+6,800
+6% +$41.2K ﹤0.01% 2475
2019
Q2
$788K Buy
110,000
+49,600
+82% +$562K ﹤0.01% 2413
2019
Q1
$802K Sell
60,400
-7,300
-11% -$77.6K ﹤0.01% 2341
2018
Q4
$533K Hold
67,700
﹤0.01% 2452
2018
Q3
$750K Hold
67,700
﹤0.01% 2455
2018
Q2
$909K Buy
+67,700
New +$847K ﹤0.01% 2360
2017
Q1
Sell
-204,256
Closed -$353K 3042
2016
Q4
$353K Sell
204,256
-6,475
-3% -$11.4K ﹤0.01% 2678
2016
Q3
$409K Sell
210,731
-24,243
-10% -$48.2K ﹤0.01% 2600
2016
Q2
$409K Hold
234,974
﹤0.01% 2583
2016
Q1
$317K Hold
234,974
﹤0.01% 2564
2015
Q4
$397K Hold
234,974
﹤0.01% 2528
2015
Q3
$456K Hold
234,974
﹤0.01% 2517
2015
Q2
$632K Hold
234,974
﹤0.01% 2506
2015
Q1
$1.63M Hold
234,974
﹤0.01% 1879
2014
Q4
$2.31M Hold
234,974
﹤0.01% 1645
2014
Q3
$1.61M Buy
+234,974
New +$1.44M ﹤0.01% 1878

Other funds holding CBAY

AllianceBernstein's CBAY Position: Q1 2024 in Review

AllianceBernstein sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 349,739 shares — an estimated $8.26M sold.

AllianceBernstein first reported a position in CBAY in Q3 2014 and held it in 29 quarters. The position peaked at $8.26M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • AllianceBernstein reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • AllianceBernstein sold 349,739 Cymabay Therapeutics shares in Q1 2024, an estimated $8.26M.
  • AllianceBernstein first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 29 quarters.
  • AllianceBernstein's Cymabay Therapeutics position peaked at $8.26M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on AllianceBernstein's 13F filing for Q1 2024, filed 14 May 2024.